Re-tasking the use of pre-existing medications and potential therapeutic options for coronavirus disease (COVID-19): systematic review of clinical studies.
Identifieur interne : 000D66 ( Main/Exploration ); précédent : 000D65; suivant : 000D67Re-tasking the use of pre-existing medications and potential therapeutic options for coronavirus disease (COVID-19): systematic review of clinical studies.
Auteurs : Bushra Hassan Marouf [Iraq] ; Kawa Dizaye [Iraq]Source :
- Drug discoveries & therapeutics [ 1881-784X ] ; 2020.
Descripteurs français
- KwdFr :
- AMP (administration et posologie), AMP (analogues et dérivés), Alanine (administration et posologie), Alanine (analogues et dérivés), Antirhumatismaux (administration et posologie), Antiviraux (administration et posologie), Betacoronavirus (effets des médicaments et des substances chimiques), Betacoronavirus (métabolisme), Essais cliniques comme sujet (méthodes), Humains (MeSH), Hydroxychloroquine (administration et posologie), Infections à coronavirus (diagnostic), Infections à coronavirus (sang), Infections à coronavirus (traitement médicamenteux), Pandémies (MeSH), Pneumopathie virale (diagnostic), Pneumopathie virale (sang), Pneumopathie virale (traitement médicamenteux), Repositionnement des médicaments (méthodes), Repositionnement des médicaments (tendances).
- MESH :
- administration et posologie : AMP, Alanine, Antirhumatismaux, Antiviraux, Hydroxychloroquine.
- analogues et dérivés : AMP, Alanine.
- diagnostic : Infections à coronavirus, Pneumopathie virale.
- effets des médicaments et des substances chimiques : Betacoronavirus.
- métabolisme : Betacoronavirus.
- méthodes : Essais cliniques comme sujet, Repositionnement des médicaments.
- sang : Infections à coronavirus, Pneumopathie virale.
- tendances : Repositionnement des médicaments.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- Humains, Pandémies.
English descriptors
- KwdEn :
- Adenosine Monophosphate (administration & dosage), Adenosine Monophosphate (analogs & derivatives), Alanine (administration & dosage), Alanine (analogs & derivatives), Antirheumatic Agents (administration & dosage), Antiviral Agents (administration & dosage), Betacoronavirus (drug effects), Betacoronavirus (metabolism), COVID-19 (MeSH), Clinical Trials as Topic (methods), Coronavirus Infections (blood), Coronavirus Infections (diagnosis), Coronavirus Infections (drug therapy), Drug Repositioning (methods), Drug Repositioning (trends), Humans (MeSH), Hydroxychloroquine (administration & dosage), Pandemics (MeSH), Pneumonia, Viral (blood), Pneumonia, Viral (diagnosis), Pneumonia, Viral (drug therapy), SARS-CoV-2 (MeSH).
- MESH :
- chemical , administration & dosage : Adenosine Monophosphate, Alanine, Antirheumatic Agents, Antiviral Agents, Hydroxychloroquine.
- chemical , analogs & derivatives : Adenosine Monophosphate, Alanine.
- blood : Coronavirus Infections, Pneumonia, Viral.
- diagnosis : Coronavirus Infections, Pneumonia, Viral.
- drug effects : Betacoronavirus.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- metabolism : Betacoronavirus.
- methods : Clinical Trials as Topic, Drug Repositioning.
- trends : Drug Repositioning.
- COVID-19, Humans, Pandemics, SARS-CoV-2.
Abstract
With the emergence of coronavirus disease 2019 (COVID-19) in late December 2019, many clinical studies on a group of the pre-existing medications have been conducted to treat this disease. The purpose of this review was to compile the clinical evidences on the use of the pre-existing medications and potential therapeutic options for the management of COVID-19. We reviewed the literature to highlight the clinical studies on the use of these medications to be available as a scientific overview for further perspectives. Inadequate clinical evidences are available to be affirmed for the repurposing of old medications, and large scale clinical studies are needed to be carried out to further confirm the use of these agents. The clinical use of these medications should be well explained and follow the framework of Monitored Emergency use of Unregistered Interventions (MEURI) of World Health Organization (WHO).
DOI: 10.5582/ddt.2020.03035
PubMed: 32669519
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Re-tasking the use of pre-existing medications and potential therapeutic options for coronavirus disease (COVID-19): systematic review of clinical studies.</title>
<author><name sortKey="Marouf, Bushra Hassan" sort="Marouf, Bushra Hassan" uniqKey="Marouf B" first="Bushra Hassan" last="Marouf">Bushra Hassan Marouf</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology and Toxicology, College of Pharmacy, University of Sulaimani, Sulaimani, Kurdistan Region, Iraq.</nlm:affiliation>
<country xml:lang="fr">Iraq</country>
<wicri:regionArea>Department of Pharmacology and Toxicology, College of Pharmacy, University of Sulaimani, Sulaimani, Kurdistan Region</wicri:regionArea>
<wicri:noRegion>Kurdistan Region</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dizaye, Kawa" sort="Dizaye, Kawa" uniqKey="Dizaye K" first="Kawa" last="Dizaye">Kawa Dizaye</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Basic Science, College of Medicine, Hawler Medical University, Erbil, Kurdistan Region, Iraq.</nlm:affiliation>
<country xml:lang="fr">Iraq</country>
<wicri:regionArea>Department of Basic Science, College of Medicine, Hawler Medical University, Erbil, Kurdistan Region</wicri:regionArea>
<wicri:noRegion>Kurdistan Region</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32669519</idno>
<idno type="pmid">32669519</idno>
<idno type="doi">10.5582/ddt.2020.03035</idno>
<idno type="wicri:Area/Main/Corpus">001135</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001135</idno>
<idno type="wicri:Area/Main/Curation">001135</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001135</idno>
<idno type="wicri:Area/Main/Exploration">001135</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Re-tasking the use of pre-existing medications and potential therapeutic options for coronavirus disease (COVID-19): systematic review of clinical studies.</title>
<author><name sortKey="Marouf, Bushra Hassan" sort="Marouf, Bushra Hassan" uniqKey="Marouf B" first="Bushra Hassan" last="Marouf">Bushra Hassan Marouf</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology and Toxicology, College of Pharmacy, University of Sulaimani, Sulaimani, Kurdistan Region, Iraq.</nlm:affiliation>
<country xml:lang="fr">Iraq</country>
<wicri:regionArea>Department of Pharmacology and Toxicology, College of Pharmacy, University of Sulaimani, Sulaimani, Kurdistan Region</wicri:regionArea>
<wicri:noRegion>Kurdistan Region</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dizaye, Kawa" sort="Dizaye, Kawa" uniqKey="Dizaye K" first="Kawa" last="Dizaye">Kawa Dizaye</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Basic Science, College of Medicine, Hawler Medical University, Erbil, Kurdistan Region, Iraq.</nlm:affiliation>
<country xml:lang="fr">Iraq</country>
<wicri:regionArea>Department of Basic Science, College of Medicine, Hawler Medical University, Erbil, Kurdistan Region</wicri:regionArea>
<wicri:noRegion>Kurdistan Region</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Drug discoveries & therapeutics</title>
<idno type="eISSN">1881-784X</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine Monophosphate (administration & dosage)</term>
<term>Adenosine Monophosphate (analogs & derivatives)</term>
<term>Alanine (administration & dosage)</term>
<term>Alanine (analogs & derivatives)</term>
<term>Antirheumatic Agents (administration & dosage)</term>
<term>Antiviral Agents (administration & dosage)</term>
<term>Betacoronavirus (drug effects)</term>
<term>Betacoronavirus (metabolism)</term>
<term>COVID-19 (MeSH)</term>
<term>Clinical Trials as Topic (methods)</term>
<term>Coronavirus Infections (blood)</term>
<term>Coronavirus Infections (diagnosis)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Drug Repositioning (methods)</term>
<term>Drug Repositioning (trends)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (administration & dosage)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (blood)</term>
<term>Pneumonia, Viral (diagnosis)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>SARS-CoV-2 (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>AMP (administration et posologie)</term>
<term>AMP (analogues et dérivés)</term>
<term>Alanine (administration et posologie)</term>
<term>Alanine (analogues et dérivés)</term>
<term>Antirhumatismaux (administration et posologie)</term>
<term>Antiviraux (administration et posologie)</term>
<term>Betacoronavirus (effets des médicaments et des substances chimiques)</term>
<term>Betacoronavirus (métabolisme)</term>
<term>Essais cliniques comme sujet (méthodes)</term>
<term>Humains (MeSH)</term>
<term>Hydroxychloroquine (administration et posologie)</term>
<term>Infections à coronavirus (diagnostic)</term>
<term>Infections à coronavirus (sang)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (diagnostic)</term>
<term>Pneumopathie virale (sang)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Repositionnement des médicaments (méthodes)</term>
<term>Repositionnement des médicaments (tendances)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adenosine Monophosphate</term>
<term>Alanine</term>
<term>Antirheumatic Agents</term>
<term>Antiviral Agents</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adenosine Monophosphate</term>
<term>Alanine</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>AMP</term>
<term>Alanine</term>
<term>Antirhumatismaux</term>
<term>Antiviraux</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>AMP</term>
<term>Alanine</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Clinical Trials as Topic</term>
<term>Drug Repositioning</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Essais cliniques comme sujet</term>
<term>Repositionnement des médicaments</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="tendances" xml:lang="fr"><term>Repositionnement des médicaments</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Drug Repositioning</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>COVID-19</term>
<term>Humans</term>
<term>Pandemics</term>
<term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Humains</term>
<term>Pandémies</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">With the emergence of coronavirus disease 2019 (COVID-19) in late December 2019, many clinical studies on a group of the pre-existing medications have been conducted to treat this disease. The purpose of this review was to compile the clinical evidences on the use of the pre-existing medications and potential therapeutic options for the management of COVID-19. We reviewed the literature to highlight the clinical studies on the use of these medications to be available as a scientific overview for further perspectives. Inadequate clinical evidences are available to be affirmed for the repurposing of old medications, and large scale clinical studies are needed to be carried out to further confirm the use of these agents. The clinical use of these medications should be well explained and follow the framework of Monitored Emergency use of Unregistered Interventions (MEURI) of World Health Organization (WHO).</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32669519</PMID>
<DateCompleted><Year>2020</Year>
<Month>07</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1881-784X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>14</Volume>
<Issue>3</Issue>
<PubDate><Year>2020</Year>
</PubDate>
</JournalIssue>
<Title>Drug discoveries & therapeutics</Title>
<ISOAbbreviation>Drug Discov Ther</ISOAbbreviation>
</Journal>
<ArticleTitle>Re-tasking the use of pre-existing medications and potential therapeutic options for coronavirus disease (COVID-19): systematic review of clinical studies.</ArticleTitle>
<Pagination><MedlinePgn>109-116</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.5582/ddt.2020.03035</ELocationID>
<Abstract><AbstractText>With the emergence of coronavirus disease 2019 (COVID-19) in late December 2019, many clinical studies on a group of the pre-existing medications have been conducted to treat this disease. The purpose of this review was to compile the clinical evidences on the use of the pre-existing medications and potential therapeutic options for the management of COVID-19. We reviewed the literature to highlight the clinical studies on the use of these medications to be available as a scientific overview for further perspectives. Inadequate clinical evidences are available to be affirmed for the repurposing of old medications, and large scale clinical studies are needed to be carried out to further confirm the use of these agents. The clinical use of these medications should be well explained and follow the framework of Monitored Emergency use of Unregistered Interventions (MEURI) of World Health Organization (WHO).</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marouf</LastName>
<ForeName>Bushra Hassan</ForeName>
<Initials>BH</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, College of Pharmacy, University of Sulaimani, Sulaimani, Kurdistan Region, Iraq.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dizaye</LastName>
<ForeName>Kawa</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Department of Basic Science, College of Medicine, Hawler Medical University, Erbil, Kurdistan Region, Iraq.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D000078182">Systematic Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Japan</Country>
<MedlineTA>Drug Discov Ther</MedlineTA>
<NlmUniqueID>101493809</NlmUniqueID>
<ISSNLinking>1881-7831</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber>
<NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>415SHH325A</RegistryNumber>
<NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber>
<NameOfSubstance UI="D000409">Alanine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="N">Adenosine Monophosphate</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
<QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
<Keyword MajorTopicYN="N">clinical studies</Keyword>
<Keyword MajorTopicYN="N">hydroxychloroquine</Keyword>
<Keyword MajorTopicYN="N">pneumonia</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>7</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>7</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>7</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32669519</ArticleId>
<ArticleId IdType="doi">10.5582/ddt.2020.03035</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Iraq</li>
</country>
</list>
<tree><country name="Iraq"><noRegion><name sortKey="Marouf, Bushra Hassan" sort="Marouf, Bushra Hassan" uniqKey="Marouf B" first="Bushra Hassan" last="Marouf">Bushra Hassan Marouf</name>
</noRegion>
<name sortKey="Dizaye, Kawa" sort="Dizaye, Kawa" uniqKey="Dizaye K" first="Kawa" last="Dizaye">Kawa Dizaye</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D66 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000D66 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidChloroV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:32669519 |texte= Re-tasking the use of pre-existing medications and potential therapeutic options for coronavirus disease (COVID-19): systematic review of clinical studies. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32669519" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a CovidChloroV1
This area was generated with Dilib version V0.6.38. |